A phase 1/2 trial of HX044 in advanced solid tumours, run by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., now recruiting.
HX044,FIH Study in Patients with Advanced Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT06649708 by Hanx Biopharmaceuticals (Wuhan) Co., Ltd., with 100 participants planned, started 2024-12-30 and due to reach its primary completion in 2025-10-31. Interventions recorded: HX044.
Shares Hangzhou Hanx Biopharmaceuticals and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.